Zolimomab aritox
Zolimomab aritox is a monoclonal antibody designed for the treatment of cancer. It was developed by Peregrine Pharmaceuticals, a biopharmaceutical company specializing in the development and manufacturing of therapeutics to treat cancer and other life-threatening diseases.
Mechanism of Action[edit | edit source]
Zolimomab aritox works by binding to the CD22 antigen on the surface of B cells, which are a type of white blood cell. The CD22 antigen is often overexpressed in certain types of cancer, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. Once bound, zolimomab aritox delivers a toxic payload to the cancer cells, causing them to die.
Clinical Trials[edit | edit source]
Zolimomab aritox has undergone several clinical trials to assess its safety and efficacy in treating cancer. In a Phase I trial, the drug was found to be well-tolerated and showed promising results in patients with refractory non-Hodgkin lymphoma. However, further development of the drug was halted due to financial constraints.
Potential Side Effects[edit | edit source]
Like all drugs, zolimomab aritox can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and fever. Serious side effects can include anaphylaxis, a severe allergic reaction.
Future Research[edit | edit source]
While the development of zolimomab aritox has been halted, research into CD22-targeted therapies continues. These therapies hold promise for the treatment of B-cell malignancies and other diseases where the CD22 antigen is overexpressed.
Translate: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Admin, Prab R. Tumpati, MD